Journal of Clinical Immunology

, Volume 34, Supplement 1, pp 70–73 | Cite as

Immunomodulation and AD – Down But Not Out

  • E. M. Knight
  • S. GandyEmail author


Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and is the most common cause of dementia in the elderly. Interventions that remove existing fibrillar and oligomeric amyloid-β (Aβ) are believed to be essential for the success of any attempt at stabilization of brain function and mitigation of cognitive decline. Many of these strategies have focused on Aβ vaccination and administration of anti-Aβ antibodies. Both active and passive immunotherapies have been successful in mouse models, but both have had limited effect in clinical trials. Intravenous immunoglobulin (IVIG) has been proposed as a potential treatment for AD following evidence for behavioral benefit in AD models and cognitive benefit in early phase 1 and phase 2 clinical trials. A phase 3 trial IVIG trial failed to meet its primary outcomes. While there was a statistically significant benefit in moderate stage AD patients who carried an APOE ε4 allele, this stabilization of cognition was evident only on neuropsychological examination. No benefit on activities of daily living was evident, therefore failing to qualify AD as a new indication for IVIG. Identifying the biologically active component (s) responsible for the neuropsychological benefit in APOE ε4-positive AD patients could enable the development of a compound with greater potency that would qualify for FDA (US Food and Drug Administration) registration.


Alzheimer’s disease immunotherapy immunoglobulin IVIG oligomer 


  1. 1.
    Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 2011;10(9):819–28.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Thies W, Bleiler L, Alzheimer’s A. 2013 Alzheimer's disease facts and figures. Alzheimer’s & dementia : the journal of the Alzheimer's Association. 2013;9(2):208–45.CrossRefGoogle Scholar
  3. 3.
    Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci. 1991;12(10):383–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Lublin AL, Gandy S. Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer's Disease. The Mount Sinai journal of medicine, New York. 2010;77(1):43–9.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14(8):837–42.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005;8(1):79–84.PubMedCrossRefGoogle Scholar
  7. 7.
    Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2007;27(11):2866–75.CrossRefGoogle Scholar
  8. 8.
    Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron. 2009;62(6):788–801.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, et al. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. The Journal of neuroscience : the official journal of the Society for Neuroscience. 1999;19(20):8876–84.Google Scholar
  10. 10.
    Tomic JL, Pensalfini A, Head E, Glabe CG. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis. 2009;35(3):352–8.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408(6815):982–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61(1):46–54.PubMedCrossRefGoogle Scholar
  14. 14.
    Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6(8):916–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370(4):322–33.PubMedCrossRefGoogle Scholar
  16. 16.
    Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol. 2012;69(8):1002–10.PubMedCrossRefGoogle Scholar
  17. 17.
    DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 2002;295(5563):2264–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 2002;5(5):452–7.PubMedGoogle Scholar
  19. 19.
    Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370(4):311–21.PubMedCrossRefGoogle Scholar
  20. 20.
    Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2012;8(4):261–71.CrossRefGoogle Scholar
  21. 21.
    Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345(10):747–55.PubMedCrossRefGoogle Scholar
  22. 22.
    Fillit H, Hess G, Hill J, Bonnet P, Toso C. IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology. 2009;73(3):180–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol. 2002;52(2):253–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Szabo P, Relkin N, Weksler ME. Natural human antibodies to amyloid beta peptide. Autoimmun Rev. 2008;7(6):415–20.PubMedCrossRefGoogle Scholar
  25. 25.
    Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol. 2002;37(7):943–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Dodel R, Balakrishnan K, Keyvani K, Deuster O, Neff F, Andrei-Selmer LC, et al. Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2011;31(15):5847–54.CrossRefGoogle Scholar
  27. 27.
    Du Y, Wei X, Dodel R, Sommer N, Hampel H, Gao F, et al. Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain : a journal of neurology. 2003;126(Pt 9):1935–9.CrossRefGoogle Scholar
  28. 28.
    Gold M, Mengel D, Roskam S, Dodel R, Bach JP. Mechanisms of action of naturally occurring antibodies against beta-amyloid on microglia. J Neuroinflammation. 2013;10:5.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Klaver AC, Finke JM, Digambaranath J, Balasubramaniam M, Loeffler DA. Antibody concentrations to Abeta1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations. Int Immunopharmacol. 2010;10(1):115–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Istrin G, Bosis E, Solomon B. Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide. J Neurosci Res. 2006;84(2):434–43.PubMedCrossRefGoogle Scholar
  31. 31.
    Magga J, Puli L, Pihlaja R, Kanninen K, Neulamaa S, Malm T, et al. Human intravenous immunoglobulin provides protection against Abeta toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation. 2010;7:90.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Puli L, Pomeshchik Y, Olas K, Malm T, Koistinaho J, Tanila H. Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease. J Neuroinflammation. 2012;9:105.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Gong B, Pan Y, Zhao W, Knable L, Vempati P, Begum S, et al. IVIG immunotherapy protects against synaptic dysfunction in Alzheimer's disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C/EBP signaling pathway. Mol Immunol. 2013;56(4):619–29.PubMedCrossRefGoogle Scholar
  34. 34.
    Dodel R, Neff F, Noelker C, Pul R, Du Y, Bacher M, et al. Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs. 2010;70(5):513–28.PubMedCrossRefGoogle Scholar
  35. 35.
    Loeffler DA. Intravenous immunoglobulin and Alzheimer's disease: what now? J Neuroinflammation. 2013;10(1):70.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Dodel RC, Du Y, Depboylu C, Hampel H, Frolich L, Haag A, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004;75(10):1472–4.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. 2009;30(11):1728–36.PubMedCrossRefGoogle Scholar
  38. 38.
    Shayan G, Adamiak B, Relkin NR, Lee KH. Longitudinal analysis of novel Alzheimer's disease proteomic cerebrospinal fluid biomarkers during intravenous immunoglobulin therapy. Electrophoresis. 2012;33(13):1975–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Tsakanikas D, Shah K, Flores C, Assuras S, Relkin NR. P4-351: Effects of uninterrrupted intravenous immunoglobulin treatment of Alzheimer's disease for nine months. Alzheimer's & Dementia: The Journal of the Alzheimer's Association. 2008;4 (4):T776-T.Google Scholar
  40. 40.
    Relkin N, Bettger L, Tsakanikas D, Ravdin L. Three-year follow-up on the IVIg for Alzheimer's phase II study. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2012;8(4):589.CrossRefGoogle Scholar
  41. 41.
    Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Forster S, et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 2013;12(3):233–43.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Departments of Neurology and Psychiatry and Alzheimer’s Disease Research CenterIcahn School of Medicine at Mount SinaiNew YorkUSA
  2. 2.James J. Peters Veterans Affairs Medical CenterBronx New YorkUSA

Personalised recommendations